Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Conjugate or complex
Reexamination Certificate
2005-02-22
2005-02-22
Smith, Lynette R. F. (Department: 1645)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Conjugate or complex
C424S258100, C424S251100, C424S184100, C424S197110, C424S234100, C424S009200, C424S192100, C424S195110, C424S236100, C424S725000, C424S240100, C424S244100, C530S403000, C530S404000, C530S405000, C530S406000
Reexamination Certificate
active
06858211
ABSTRACT:
This invention relates to conjugates of the O-specific polysaccharide ofE. coliO157 with a carrier, and compositions thereof, and to methods of using of these conjugates and/or compositions thereof for eliciting an immunogenic response in mammals, including responses which provide protection against, or reduce the severity of, bacterial infections. More particularly it relates to the use of polysaccharides containing the tetrasaccharide repeat unit: (→3)-α-D-GalpNAc-(1→2)-α-D-PerpNAc-(1→3)-α-L-Fucp-(1→4)-β-D-Glcp-(1→), and conjugates thereof, to induce serum antibodies having bactericidal (killing) activity against hemolytic-uremic syndrome (HUS) causingE. coli,in particularE. coliO157. The conjugates, and compositions thereof, are useful as vaccines to induce serum antibodies which have bactericidal or bacteriostatic activity against againstE. coli,in particularE. coliO157, and are useful to prevent and/or treat illnesses caused byE. coliO157.The invention further relates to the antibodies which immunoreact with the O-specific polysaccharide ofE. coliO157 and/or the carrier, that are induced by these conjugates and/or compositions thereof. The invention also relates to methods and kits using one or more of the polysaccharides, conjugates or antibodies described above.
REFERENCES:
patent: 4141970 (1979-02-01), Chidlow et al.
patent: 4356170 (1982-10-01), Jennings et al.
patent: 4711779 (1987-12-01), Porro et al.
patent: 5153312 (1992-10-01), Porro
patent: 5204097 (1993-04-01), Arnon et al.
patent: 5306492 (1994-04-01), Porro
patent: 5354661 (1994-10-01), Doyle et al.
patent: 5370872 (1994-12-01), Cryz et al.
patent: 5371197 (1994-12-01), Marburg et al.
patent: 5512282 (1996-04-01), Krivan et al.
patent: 5552144 (1996-09-01), Samuel et al.
patent: 5585100 (1996-12-01), Mond et al.
patent: 5693326 (1997-12-01), Lees
patent: 5747272 (1998-05-01), O'Brien et al.
patent: 5773007 (1998-06-01), Penney et al.
patent: 5785973 (1998-07-01), Bixler et al.
patent: 5955293 (1999-09-01), Keusch et al.
patent: 6162441 (2000-12-01), Chae et al.
patent: 6310043 (2001-10-01), Bundle et al.
patent: 6410024 (2002-06-01), Burnie et al.
patent: 6472506 (2002-10-01), Moreau et al.
Ashkenazi, S et al, J. Pediatr, Dec. 1988, vol. 113(6), pp. 1008-1014.*
Bitzan, Me t al, Infection (German&), May-Jun. 1993, vol. 21(3), pp. 140-145.*
Chart, H et al, Journal of Clinical Microbiology, Feb. 1989, vol. 27(2), pp. 285-290, Feb. 1989.*
Robbins, John B. et al, Reviews of Infectious Disease, vol. 13(Suppl. 4), pp. S362-S365, 1991.*
Konadu, E et al, Infection and Immunity, vol. 62(11), pp. 5048-5054, Nov. 1994.*
Ludwig, Kerstin et al, Journal of Infectious Disease, vol. 186, pp. 566-569, 2002.*
Conlan, J. Wayne et al, Can. J. Microbiol. Rev., vol. 45(4), pp. 279-286, 1999, abstact only.*
Konadu, EY et al , 1998, The Journal of Infectious Diseases, vol. 177, February, pp. 383-387.*
Konadu, EY et al, Nov. 1994, Infection and Immunity, Vool 62(11), pp. 5048-5054.*
Ashkenazi, S et al, J. Pediatr., Dec. 1988, vol. 113(6), pp. 1008-1014.*
Bitzan, M et al, Infection (German), May-Jun. 1993, vol. 21(3), pp. 140-145.*
Chart, H et al, J. Clinic. Microbiol, vol. 27(2), pp. 285-290, Feb. 1989.*
Vernozy-Rozand, C. Journal of Applied Microbiology, May 1997, vol. 82(5), pp. 537-551.*
Harari, I et al, Infection adn Immunity, Jun. 1988, vol. 56(6), pp. 1618-1624.*
Johnson, RP et al, Infection and Immunity, May 1996, vol. 64(5), pp. 1879-1883.*
Robbins, JB et al, Review of Infectious Dieases, 1991, vol. 13 (suppl. 4), pp. S362-S365.*
Strockbine, NA et al, Infection and Immunity, Dec. 1985, vol. 50(3), pp. 695-700.*
Taylor, DN et al, Infection and Immunity, vol. 61(9), pp. 3678-3687, Sep. 1993.*
Islam, MS et al, J. Clin. Lab. Immunol. 1990, vol. 33 (1), pp. 11-16.*
Havens, PL et al, Microbiol. Immunol. vol. 36(10), pp. 1077-1085, 1992.*
Padhye, NV et al, Production and characterization of a monoclonal antibody specific for enterohemorrhagicEscherichia coliof serotypes O157:h7 and O26:H11, J. Clin. Microbiol., Jan. 1991, vol. 29(1), pp. 99-103.*
Ryd, Marie, PhD thesis, 1992, Karolinska Institutet (Sweden) (0658) vol. 55/02-C of Dissertation Abstracts International, p. 432.*
Qadri, F et al, Advances in Mucosal Immunology, Edited by J. Meskecky et al, 1995, Advances in Experimental Medicine and Biology, 1995, vol. 371/B, pp. 923-926.*
Schmitt, CK et al, Infection and Immunity, vol. 59(3), pp. 1065-1073, Mar. 1991.*
Weinstein, DL et al, Infection and Immunity, vol. 57(12), pp. 3743-3750, Dec. 1989.*
Konadu et al, Jun. 26, 1997, Seide presentation, Symposium Workshop, Baltimore, Md.*
Chu, C; “Preparation, Characterization, an Immunogencity of Conjugates Composed of the O-Specific Polysaccharide ofShigella dysenteriaeType I (Shiga's Bacillus) Bound to Tetanus Toxoid”,Infection and Immunity, vol. 59, No. 12; pp 4450-4458, Dec. 1991.
Cryz, S.J, “Synthesis and Characterization ofEscherichia coli018 O-Polysaccharide Conjugate Vaccines”,Infection and Immunity, vol. 58, No. 2, pp 373-377, Feb. 1990.
Dick et al., “Glycoconjugates of Bacterial Carbohydrate Antigens a Survey and Consideration of Design and Preparation Factors”, Cruse JM, Lewis RE Jr. (eds.)Conjugate Vaccines, vol. 10, pp 48-114, 1989.
Gupta, R.K., “Comparitive Immunogencity of Conjugates Composed ofEscherichia coli0111 0-Specific Polysaccharide, Prepared by Treatment with Acetic Acid or Hydrazine, Bound to Tetanus Toxoid by Two Synthetic Schemes”,Infection and Immunityvol. 63, No. 8., pp. 2805-2810, Aug. 1995.
Konadu et al, “Investigational Vaccine forEscherichia coli0157: Phase 1 Study of 0157 O-Specific Polysaccharide-Pseudomonas aeruginosa Recombinant Exoprotein A Conjugates in Adults”,The Journal of Infectious Diseases. Feb. 1998, vol. 177, pp 383-387. (mailed out to the public on Jan. 21, 1998).
Konadu et al, “Preparation, Characterization, and Immunological Properties in Mice ofEscherichia coli0157 0-Specific Polysaccharide-Protein Conjugate Vaccines”,Infection and Immunity, vol. 62, No. 11, pp 5048-5054, Nov. 1994.
Robbins et al, “O-Specific Side-Chain Toxin-Protein Conjugates as Parental Vaccines for the Prevention of Shigellosis and Related Diseases”,Reviews of Infectious Diseases, vol. 13, No. 4 supplement, pp S362-S365, 1991.
Sjogren et al, “Influence of Shiga-like toxin production in Enteric Infection with an EnteropathogenicEscherichia colistrain”,Gastroenterology, vol. 92, No. 5, Part 2 pp 1643, May 1987.
Taylor et al, “Synthesis, Characterization, and Clinical Evaluation of Conjugate Vaccines Composed of the 0-Specific Polysaccharides ofShigella dysenteriaeType 1,Shigella flexneriType 2a, andShigella sonnei(Plesiomonas shigelloides) Bound to Bacterial Toxoids”,Infection and Immunity, vol. 61, pp 3678-3687, Sep. 1993.
Human Testing ofE. coli0157:H7 Vaccine,Food Chemical News,, vol. 37 No. 19 (Abstract), Jul. 3, 1995.
Lovett, R.A., “Training a Molecular Gun on KillerE. coli”, Science282: 1404 , Nov. 20, 1998.
Robbins et al, “Hypothesis for Vaccine Development: Protective Immunity to Enteric Diseases Caused by Nontyphoidal Salmonellae and Shigellae May be Conferred by Serum IgG Antibodies to the O-Specific Polysaccharide of their Lipopolysaccharides”,Clinical Infectious Diseases, vol. 15 pp 346-361,1992.
Johnson, R.P., “Serum Antibody Responses of Cattle Following Experimental Infection withEscherichia coliO157:H7”,Infection and Immunity, vol. 64, pp. 1879-1883, May 1996.
Conference Discusses Ways to ReduceE. coliat Farm and Slaughter,Food Chemical News, vol. 37, No. 9 (Abstract) Apr. 24, 1995.
E. coli, VTEC Research Reviewed at IAMFES Meeting,Food Chemical News, vol. 38, No. 21, (Abstract) Jul. 15, 1996.
Brief Notes: Researchers at the National Institutes of Health,Food Chemical News, vol. 39, No. 52, (Abstract) Feb. 16, 1998.
E. coliUS Experts: Food Poisoning Vaccine Works,Vaccine Weekly, (Abstract), Mar. 2, 1998.
Product News:Escherichi
Konadu Yvonne Ageyman
Robbins John B.
Szu Shousun Chen
Klarquist & Sparkman, LLP
Portner Ginny Allen
Smith Lynette R. F.
The United States of America as represented by the Department of
LandOfFree
Vaccines against Escherichia coli O157 infection does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Vaccines against Escherichia coli O157 infection, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Vaccines against Escherichia coli O157 infection will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3501219